SMMT Stock Analysis: Buy, Sell, or Hold?
SMMT - Summit Therapeutics Inc. Common Stock
$13.16
0.73 (5.87%)
▲
5d:
-1.42%
30d:
-12.15%
90d:
-24.67%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 19, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 14, 2026 at $13.31 · last confirmed Aug 18, 2026
Strength: 7.2/10
Get Alerted When SMMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SMMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SMMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SMMT is currently trading at $13.16, which is considered slightly low relative to its 30-day fair value range of $12.92 to $14.70.
Technical Outlook: Technically, SMMT is in a strong downtrend. Immediate support is located at $12.07, while resistance sits at $15.75. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $28.56 (+123.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SMMT is in a strong downtrend. Immediate support is located at $12.07, while resistance sits at $15.75. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $28.56 (+123.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$12.92 -
$14.70
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 123.5% below Wall St target ($28.56)
- NEUTRAL: Bottoming setup forming (44/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$12.92 -
$14.70
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$12.07
Resistance Level
$15.75
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.37
Wall Street Target
$28.56
(+123.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 23, 2026 5:18 PM ET
Data refreshes hourly during market hours. Next update: 6:18 PM
Data refreshes hourly during market hours. Next update: 6:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
